**Patient Acknowledgment of ESA Benefits and Risks**

Aranesp® (darbepoetin alfa), Epogen® (epoetin alfa), and Procrit® (epoetin alfa) are prescription medicines used to treat anemia. They are in a class of medicines called *erythropoiesis stimulating agents,* or ESAs. These medicines are different from each other, so your healthcare provider will decide which one is right for you.

**Benefits:** People with anemia have a lower-than-normal number of red blood cells (RBCs). ESAs work like the human protein called *erythropoietin* to help your body make more RBCs. ESAs are used to reduce or avoid the need for RBC transfusions.

**Risks:** ESAs may make my tumor grow faster and I may die sooner.

---

**Written Permission to Share Information**

I permit my healthcare provider to share this form with Amgen and Janssen Products, LP (the Sponsors) and their contractors that manage certain aspects of the ESA APPRISE Oncology Program (the Contractors). The Program Sponsors and Contractors agree to keep my information secure. They will use it only to make sure Program rules are being followed.

---

**Healthcare Provider Acknowledgment**

I acknowledge that prior to the initiation of this new course of ESA therapy:

- I counseled the patient on the risks and benefits of ESAs by reviewing the Acknowledgment Form.
- I discussed all concerns and answered all questions the patient had about treatment with ESAs to the best of my ability.
- The patient or patient representative signed the Acknowledgment Form in my presence and I provided a copy of the signed Acknowledgment Form to the patient.

---

*Aranesp® and Epogen®/Procrit® are different drugs with distinct dosing schedules.*

†Or modified version consistent with the allowable changes.

Aranesp® and Epogen® are registered trademarks of Amgen Inc.

Procrit® is a registered trademark of Janssen Products, LP.

V5 10/13